Medtronic touts Japanese data for drug-coated balloon

Medtronic (NYSE:MDT) touted 1 year data from the In.Pact SFA Japan trial of its drug-coated balloon compared to plain balloon angioplasty.

The trial enrolled 100 patients, 68 of whom were treated with the drug-coated balloon and 32 with plain balloon angioplasty. Primary patency, or restoration of adequate blood flow through the treated segment of diseased artery, was 89.2% for the DCB group and 48.4% for the control group at 12-months follow-up.

Get the full story at our sister site, Drug Delivery Business News.

The post Medtronic touts Japanese data for drug-coated balloon appeared first on MassDevice.

from MassDevice http://ift.tt/2kqubzr